Corticosteroids

Antares Pharma Announces FDA Acceptance of IND Application for ATRS-1902 for Adrenal Crisis Rescue

Retrieved on: 
Thursday, July 22, 2021
Health sciences, Health care, Health, Food and Drug Administration, Glucocorticoids, Drug Safety, Corticosteroids, Alcohols, Hydrocortisone, New Drug Application, Investigational New Drug, Pharmaceutical industry

EWING, N.J., July 22, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the Company), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug Application (IND) for ATRS-1902 for adrenal crisis rescue.

Key Points: 
  • EWING, N.J., July 22, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the Company), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug Application (IND) for ATRS-1902 for adrenal crisis rescue.
  • The FDA acceptance of this IND is an important milestone in the development of a novel formulation and delivery of hydrocortisone in a crisis situation.
  • Current standard of care for the management of acute adrenal crises includes Solu-Cortef, which is an anti-inflammatory glucocorticoid.
  • Robert F. Apple, President and Chief Executive Officer of Antares Pharma, added, We are pleased to be able to advance the development of our proprietary pipeline with the FDA acceptance of this IND.

EPI Health and MC2 Therapeutics announces U.S. Launch of Wynzora® Cream for Plaque Psoriasis (calcipotriene and betamethasone dipropionate w/w 0.005%/0.064%)

Retrieved on: 
Monday, July 19, 2021
Drugs, Steroids, Organ systems, Corticosteroids, Combination drugs, Antipsoriatics, Glucocorticoids, Calcipotriol/betamethasone dipropionate, Betamethasone dipropionate, Betamethasone, Psoriasis, Calcipotriol

"Calcipotriene and betamethasone dipropionate are well-established molecules for the treatment ofplaque psoriasis, with proven efficacy, safety and tolerability.

Key Points: 
  • "Calcipotriene and betamethasone dipropionate are well-established molecules for the treatment ofplaque psoriasis, with proven efficacy, safety and tolerability.
  • Until now they could not be combinedinto an aqueous cream, which is less greasy and more user-friendly than other formulations."
  • Wynzora Cream is based on PADTechnology, which uniquely enables stability of both calcipotriene and betamethasone dipropionate in aconvenient-to-use aqueous formulation.
  • Wynzora (calcipotriene and betamethasone dipropionate) Cream is indicated for plaque psoriasis inadults.It is notknown ifWynzoraCream is safeand effectivein children.

EPI Health and MC2 Therapeutics announces U.S. Launch of Wynzora® Cream for Plaque Psoriasis (calcipotriene and betamethasone dipropionate w/w 0.005%/0.064%)

Retrieved on: 
Monday, July 19, 2021
Drugs, Steroids, Organ systems, Combination drugs, Corticosteroids, Antipsoriatics, Calcipotriol/betamethasone dipropionate, Betamethasone dipropionate, Betamethasone, Psoriasis, Calcipotriol, Topical steroid

Now available: Wynzora Cream (calcipotriene and betamethasone dipropionate, w/w0.005%/0.064%) once-daily topical treatment of plaque psoriasis in adults 18 years of age orolderintroduces useof PAD Technology.

Key Points: 
  • Now available: Wynzora Cream (calcipotriene and betamethasone dipropionate, w/w0.005%/0.064%) once-daily topical treatment of plaque psoriasis in adults 18 years of age orolderintroduces useof PAD Technology.
  • "Calcipotriene and betamethasone dipropionate are well-established molecules for the treatment ofplaque psoriasis, with proven efficacy, safety and tolerability.
  • Wynzora Cream is based on PADTechnology, which uniquely enables stability of both calcipotriene and betamethasone dipropionate in aconvenient-to-use aqueous formulation.
  • Wynzora (calcipotriene and betamethasone dipropionate) Cream is indicated for plaque psoriasis inadults.It is notknown ifWynzoraCream is safeand effectivein children.

Glycomine’s Natural History Study Informs Potentially Lifesaving Update to Standard of Care for PMM2-CDG Patients

Retrieved on: 
Tuesday, June 29, 2021
Children, Biotechnology, Baby, Maternity, Health, Pharmaceutical, Other Science, Research, Genetics, Consumer, Science, Clinical trials, Endocrine system, Medical specialties, Organ systems, Adrenal gland disorders, Glucocorticoids, Corticosteroids, Congenital disorders of glycosylation, PMM2 deficiency, Adrenal insufficiency, Adrenocorticotropic hormone, Cortisol, Adrenal gland, PMM2-CDG (CDG-Ia), GLM101, a Potential Treatment for PMM2-CDG, Glycomine, Inc., PMM2-CDG (CDG-IA), GLM101, A POTENTIAL TREATMENT FOR PMM2-CDG, GLYCOMINE, INC.

These data provide key insights to improve standard of care, as early recognition of adrenal insufficiency and initiation of glucocorticoid replacement therapy and stress dosing could be lifesaving.

Key Points: 
  • These data provide key insights to improve standard of care, as early recognition of adrenal insufficiency and initiation of glucocorticoid replacement therapy and stress dosing could be lifesaving.
  • The authors conclude that morning cortisol and ACTH levels should be evaluated at least annually for all patients with PMM2-CDG.
  • Through an international collaboration, this study was the first to identify that patients with PMM2-CDG are at risk for secondary adrenal insufficiency and to suggest that morning cortisol and ACTH monitoring should become part of standard care in these patients.
  • The natural history study completed enrollment with 139 PMM2-CDG patients at 11 sites around the world (ClinicalTrials.gov Identifier: NCT03173300 ).

Worldwide Keloid Treatment Industry to 2026 - Growing Awareness Among People Regarding the Availability of Treatment Options Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 24, 2021
Health, General Health, Health sciences, Pharmacology, Health, Dosage forms, Corticosteroids, Keloid, Topical medication, Silicone, Gel, Scar

The global keloid treatment market is expected to grow due to the rapid development made by the technologically upgraded skincare products.

Key Points: 
  • The global keloid treatment market is expected to grow due to the rapid development made by the technologically upgraded skincare products.
  • Also, growing awareness amongst the people regarding the availability of treatment options and other products available to cure keloid is a key factor in helping the keloid treatment market growth.
  • Based on product type, the global keloid treatment market is segmented into Elastic Wraps, Sprays, Ointment, Creams, Oils, Topical Gels & Gel Sheets.
  • Based on treatment, the global keloid treatment market is segmented into ligature, radiation therapy, surgical treatment, laser treatment, steroid injections, corticosteroid injections (intralesional steroids), Silicone gel or sheeting, interferon.

Sparrow Pharmaceuticals Presents Data on SPI-62 at the European Congress of Endocrinology

Retrieved on: 
Saturday, May 22, 2021
Health, Clinical trials, Research, Pharmaceutical, Science, Biotechnology, Steroids, Endocrine system, Glucocorticoids, Organ systems, Corticosteroids, Anxiety, Cortisol, Otologicals, Pregnanes

Sparrow\xe2\x80\x99s novel approach to treatment of CS is based on recognition that the predominant source of intracellular cortisol is HSD-1.

Key Points: 
  • Sparrow\xe2\x80\x99s novel approach to treatment of CS is based on recognition that the predominant source of intracellular cortisol is HSD-1.
  • That\xe2\x80\x99s formed mostly by HSD-1,\xe2\x80\x9d said Dr. David Katz, Chief Scientific Officer of Sparrow.
  • \xe2\x80\x9cSPI-62 can reduce that pool by up to 90% and was associated with favorable clinical changes in patients with diabetes.
  • Its lead product, SPI-62, is an oral, small molecule, novel therapeutic treatment designed to target the source of active intracellular corticosteroids in key tissues.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210522005003/en/\n'

Global Corticosteroids Market Report 2021: COVID-19 Implications and Growth Forecasts to 2025 & 2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 12, 2021
Health, Pharmaceutical, Companies, Life sciences, Health sciences, Corticosteroids, Medical research, CAC 40, Sanofi, Pfizer, Novartis, AstraZeneca

b'The "Corticosteroids Global Market Report 2021: COVID-19 Implications and Growth to 2030" report has been added to ResearchAndMarkets.com\'s offering.\nMajor players in the corticosteroids therapy market are Sumitomo, Pfizer, Novartis, Merck, Sanofi, Johnson and Johnson, GSK, AstraZeneca, Cipla, and LEO Pharma.\nThe global corticosteroids market is expected to grow from $4.47 billion in 2020 to $4.56 billion in 2021 at a compound annual growth rate (CAGR) of 2%.

Key Points: 
  • b'The "Corticosteroids Global Market Report 2021: COVID-19 Implications and Growth to 2030" report has been added to ResearchAndMarkets.com\'s offering.\nMajor players in the corticosteroids therapy market are Sumitomo, Pfizer, Novartis, Merck, Sanofi, Johnson and Johnson, GSK, AstraZeneca, Cipla, and LEO Pharma.\nThe global corticosteroids market is expected to grow from $4.47 billion in 2020 to $4.56 billion in 2021 at a compound annual growth rate (CAGR) of 2%.
  • The use of corticosteroids during the treatment of coronaviruses have shown positive outcomes due to their ability to modulate the inflammatory response.
  • Therefore, corticosteroids market has experienced a surge in its growth.\nSide effects associated with the long-term use of corticosteroids is negatively affecting the corticosteroids market.
  • Global Corticosteroids Therapy Forecast Market, 2020-2025F, 2030F, $ Billion\n'

China Budesonide Market Report 2021: Sales Decreased by 29.30% in 2020 - Forecast to 2025 - ResearchAndMarkets.com

Retrieved on: 
Friday, April 30, 2021
Health, Pharmaceutical, Steroids, Drugs, Glucocorticoids, Corticosteroids, Diketones, Diols, Pregnanes, Budesonide, Compound annual growth rate, Adrenal gland

b'The "Investigation Report on China\'s Budesonide Market 2021-2025" report has been added to ResearchAndMarkets.com\'s offering.\nSales of Budesonide increased from 2016 to 2019, with a CAGR of approximately 9.26%.

Key Points: 
  • b'The "Investigation Report on China\'s Budesonide Market 2021-2025" report has been added to ResearchAndMarkets.com\'s offering.\nSales of Budesonide increased from 2016 to 2019, with a CAGR of approximately 9.26%.
  • However, the sales of Budesonide decreased by 29.30% in 2020 because of the COVID-19 pandemic.
  • With the improvement of the epidemic situation, the analyst predicts that the sales of Budesonide in China will have a recovery growth in the short run.\nBudesonide is an adrenal cortex hormone medicine.
  • Thus, the analyst analyzes that in addition to the recovery growth, the sales of Budesonide will increase in 2021-2025 as the market expands.\n2 Sales of Budesonide in China, 2016-2020\n2.3 Sales of Budesonide by Dosage Form in China, 2016-2020\n'

LEO Pharma Receives Positive CHMP Opinion of Adtralza® (tralokinumab) for the Treatment of Adults With Moderate-to-Severe Atopic Dermatitis

Retrieved on: 
Friday, April 23, 2021
Health, Other Science, General Health, Research, Science, Pharmaceutical, Biotechnology, Type I hypersensitivity, Monoclonal antibodies, Tralokinumab, Medical specialties, Immunology, Atopic dermatitis, Corticosteroids, Dermatitis, Atopy, Topical steroid, Clinical medicine, Health, Other Science, General Health, Research, Science, Pharmaceutical, Biotechnology, Type I hypersensitivity, Monoclonal antibodies, Tralokinumab, Medical specialties, Immunology, Atopic dermatitis, Corticosteroids, Dermatitis, Atopy, Topical steroid, Clinical medicine, Health, Other Science, General Health, Research, Science, Pharmaceutical, Biotechnology, Type I hypersensitivity, Monoclonal antibodies, Tralokinumab, Medical specialties, Immunology, Atopic dermatitis, Corticosteroids, Dermatitis, Atopy, Topical steroid, Clinical medicine, Adtralza (tralokinumab), the pivotal ECZTRA 1, 2, and ECZTRA 3 Trials, atopic dermatitis, LEO Pharma, ADTRALZA (TRALOKINUMAB), THE PIVOTAL ECZTRA 1, 2, AND ECZTRA 3 TRIALS, ATOPIC DERMATITIS, LEO PHARMA

LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 93 million patients in 130 countries.

Key Points: 
  • LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 93 million patients in 130 countries.
  • For more information please visit www.LEO-Pharma.com\nBieber T. Interleukin-13: targeting an underestimated cytokine in atopic dermatitis.
  • Tralokinumab for moderate\xe2\x80\x90to\xe2\x80\x90severe atopic dermatitis: results from two 52\xe2\x80\x90week, randomized, double\xe2\x80\x90blind, multicentre, placebo\xe2\x80\x90controlled phase III trials (ECZTRA 1 and ECZTRA 2).
  • Tralokinumab plus topical corticosteroids for the treatment of moderate\xe2\x80\x90to\xe2\x80\x90severe atopic dermatitis: results from the double\xe2\x80\x90blind, randomized, multicentre, placebo\xe2\x80\x90controlled phase III ECZTRA 3 trial.

Polymyalgia Rheumatica Treatment Market to Record a Robust Growth at a CAGR of 13.60% for the Study Period (2018-2030), states DelveInsight

Retrieved on: 
Monday, March 22, 2021
Steroids, Glucocorticoids, Organ systems, Medical specialties, Corticosteroids, Prodrugs, Polymyalgia rheumatica, Hepatotoxins, Rheumatology, Prednisone, Deflazacort

The Polymyalgia Rheumatica market report also proffers an analysis of recent Polymyalgia Rheumatica treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.

Key Points: 
  • The Polymyalgia Rheumatica market report also proffers an analysis of recent Polymyalgia Rheumatica treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.
  • Clinicians often use the rapid resolution of symptoms to low prednisone doses (20 mg) to confirm Polymyalgia Rheumatica diagnosis.
  • Other alternatives to Glucocorticoids have been evaluated for Polymyalgia Rheumatica treatment, but results have been disappointing to date.
  • The corticosteroid drug deflazacort is being studied for the treatment of Polymyalgia Rheumatica.